- Ana Canha-Borges, i3S - Instituto de Investigação e Inovação em Saúde & ICBAS – Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto, Porto, Portugal & Inserm U1030 «Molecular Radiotherapy and Therapeutic Innovation»; Institute Gustave Roussy, Villejuif, France. “Decoding Radiotherapy Resistance: The Crucial Role of Macrophages in Triple Negative Breast Cancer“
- Peter J. Gawne, UCL Cancer Institute, University College London & Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary, University of London & School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom. “Investigating a GD2-targeted Radiotheranostic for High-risk Neuroblastoma using 177Lu- and 111In-labelled Dinutuximab beta“
- Chloé Lameli, CBM UPR 4301, Département Nanomédicaments et Nanosondes, CNRS, Tours, France. “Development of EGFR targeted magnetic nanovectors for a combined delivery of doxorubicin and siRNA to obtain a synergistic apoptotic effect on triple-negative breast cancer cells“
Fábio A. C. Lopes, Physics Centre of Minho and Porto Universities (CF-UM-UP), University of Minho, Braga, Portugal
Report Deadline for abstraction submission : June 27th, 2024.
The 17th international workshop edition will confront the points of view and issues of various research fields such as Chemistry, Biology, Physics, Medicine, Computer science, involved in the development of molecular and external beam radiotherapies in Oncology.
The 2024 topic will focus on therapeutic applications using lutetium-177, demonstrating the evolution of nuclear medicine, an initially diagnostic discipline that is now opening up to the prospect of therapeutic applications. Aspects of production, radiochemistry, dosimetry and imaging, such as pre-therapeutic SPECT imaging protocols, through to clinical trials will be discussed in the case of lutetium-177, but also for alpha and beta emitters as alternatives. The workshop will also address the role of nanovectors for imaging and internal & external radiotherapies. Finally, the latest advances in tumor and microenvironment targeting will be highlighted.
Report Abstract submission : before June 27th, 2024.
Registration : Deadline June 27th, 2024.
Location :This event will take place in the "Domaine de Roz Armor" in Erquy, in Côtes d'Armor, located 1.5 hours from Rennes, in West of France.
For more information please visit http://www.cgo-workshop-vecto.fr/
